Idéal Investisseur
Français English
CAC 40 : Market open
7 750,65 pts
-0.24%


Last updated : 08/10/2026 - 15h38
🏠 Home   ➤    Stock news

ADOCIA Shares Surge 26.46% Over the Week, Boosted by Analyst Recommendation

The Lyon-based company specializing in diabetes and obesity treatments experienced a particularly dynamic week, closing at €9.75 on Friday, October 10. This weekly increase of 26.46% is in stark contrast to the downturns of the CAC 40 and SBF 120, which both fell by approximately 1.7% over the same period.


ADOCIA Shares Surge 26.46% Over the Week, Boosted by Analyst Recommendation

Significant Surge on Thursday

The week was marked by a significant acceleration on Thursday, October 9, where the stock jumped 35.40% to reach €10.48, before slightly retracting to €9.75 the following day. Trading volumes skyrocketed on this occasion, with more than 2 million shares traded on Thursday, approximately 11% of the company's capital, compared to less than 300,000 shares in previous sessions. This surge is part of a particularly robust medium-term dynamic, with the stock showing a growth of 148.7% over three months and 81.56% over a year, a considerable gap compared to the Parisian indices which have increased by about 4.6% over twelve months. On Friday, despite a 7% decline from the previous day's high, volumes remained strong with 1.36 million shares traded, indicating sustained investor interest.

Sharp Rise Following Analyst Coverage

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

This sharp rise followed the initiation of coverage by Invest Securities on Thursday, October 9, with the analysis firm setting a buy recommendation and a price target of €17.90. This target price represents an upside potential of over 80% compared to the closing price on Friday, which largely explains the surge in trading volumes observed. Analysts justify their position by the significant potential of the company in the drug delivery technology segment applied to diabetes and obesity, a rapidly expanding market. The peak reached on Thursday at €10.48 now constitutes a technical resistance level to watch, while the support identified at €7.30 remains relatively distant, offering a comfortable margin in case of consolidation.



Sector Pharmacie et biotechnologies › Biotechnologies


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Revenue growth: -95,8 %
  • Net income: -8,6 millions d'euros
Guidance from the release
  • visibilité financière maintenue jusqu'au début du deuxième trimestre 2027 ; incertitude significante sur la continuité d'exploitation
Risks mentioned
  • Consommation de trésorerie de 10,1 M€ au premier semestre 2026
  • Horizon de financement limité au début du deuxième trimestre 2027
  • Chiffre d'affaires semestriel en forte baisse, de 1 031 K€ à 43 K€
Opportunities identified
  • Résultats positifs de Phase 3 de BioChaperone® Lispro en Chine et dépôt d'AMM en préparation
  • Trois études de faisabilité BioChaperone® positives avec de grandes pharmas, deux en discussions avancées
  • AdOral® Sema breveté et libre d'exploitation alors que le semaglutide devient libre de droit en 2026

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours